Stock AXIM AXIM BIOTECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company AXIM Biotechnologies, Inc. Other OTC

Equities

AXIM

US05463V1008

Biotechnology & Medical Research

Business Summary

Axim Biotechnologies, Inc. is an international healthcare diagnostic solutions development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. It has developed and commercialized two highly specialized point-of-care (POC) diagnostic tests, Ocular Immunoglobulin E (IgE) test and Lactoferrin test, which are designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient DED and non-specific allergic conjunctivitis. In addition, it is also engaged in the development of a quantitative tear MMP-9 test to measure the intensity of inflammation affecting dry eye patients. It has also developed proprietary assays for the detection of QSOX1-L in patients undergoing cancer treatment. Its products also include SARS-CoV-2 neutralizing antibody tests and a fentanyl neutralizing antibody test.

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
0 100.0 % 0 100.0 % +345.27%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % +345.27%

Managers

Managers TitleAgeSince
John Huemoeller CEO
 Chief Executive Officer 68 -
Robert Malasek DFI
 Director of Finance/CFO 55 16-06-28
Kurt Phinney COO
 Chief Operating Officer - 23-05-22
Joseph Tauber CTO
 Chief Tech/Sci/R&D Officer 67 21-09-20
Jeffrey A. Busby PRN
 Corporate Officer/Principal - 21-09-14

Members of the board

Members of the board TitleAgeSince
John Huemoeller CEO
 Chief Executive Officer 68 -
Timothy Scott BRD
 Director/Board Member 71 17-05-17
Robert Cunningham BRD
 Director/Board Member 76 17-05-17
Blake Schroeder BRD
 Director/Board Member 48 -
Peter O'Rourke BRD
 Director/Board Member 76 20-07-20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 500,000 0 0 71.61 %
Stock B 1 278,429,403 199,384,612 ( 71.61 %) 0

Shareholders

NameEquities%Valuation
Catalina Valencia
10.57 %
25,117,590 10.57 % 301 411 $
MEDICAL MARIJUANA, INC.
9.539 %
22,669,125 9.539 % 272 030 $
Glycodots LLC
8.332 %
19,800,000 8.332 % 237 600 $
John Huemoeller
2.525 %
6,000,000 2.525 % 72 000 $
Blake Schroeder
0.4246 %
1,009,000 0.4246 % 12 108 $
Timothy Scott
0.1403 %
333,333 0.1403 % 4 000 $
Robert Cunningham
0.1403 %
333,333 0.1403 % 4 000 $
Peter O'Rourke
0.1052 %
250,000 0.1052 % 3 000 $
Robert Malasek
0.0210 %
50,000 0.0210 % 600 $
Kurt Phinney
0.000000 %
0 0.000000 % - $
NameEquities%Valuation
John Huemoeller
100.00 %
500,000 100.00 % 6 000 $

Company contact information

AXIM Biotechnologies, Inc.

6191 Cornerstone Court East Suite 114

92121, San Diego

+

http://www.aximbiotech.com
address AXIM Biotechnologies, Inc.(AXIM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AXIM Stock
  4. AXIM Stock
  5. Company AXIM Biotechnologies, Inc.